Cogent Biosciences (COGT) News Today $12.49 +0.29 (+2.38%) Closing price 04:00 PM EasternExtended Trading$12.48 -0.01 (-0.08%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Why Is Cogent Biosciences Up Today?Toggle Visibility of Why Is Cogent Biosciences Up Today?Below is a summary of recent analyst actions and price moves affecting Cogent Biosciences, Inc. (NASDAQ:COGT). Positive Sentiment: Citigroup raised its price objective on COGT from $15.00 to $22.00 and reiterated a “Buy” rating. Citigroup Issues Positive Forecast for Cogent Biosciences Positive Sentiment: Analysts at Citigroup boosted their COGT price target by 76.1%, from $15.00 to $22.00. Benzinga Positive Sentiment: Shares of COGT reached a new 52-week high on strong volume, prompting discussions on whether it’s a buying opportunity. Cogent Biosciences Reaches New 12-Month High Negative Sentiment: Leerink Partners cut its Q2 2025 EPS estimate for COGT from ($0.63) to ($0.65), reflecting concerns over near-term cash flow. Leerink Partnrs Issues Pessimistic Outlook for COGT Earnings Negative Sentiment: Leerink Partners also trimmed its FY2027 EPS forecast for COGT to $0.96 from $1.04, signaling lower long-term profitability expectations. FY2027 Earnings Forecast for COGT Issued By Leerink Partnrs Posted 4h agoAI Generated. May Contain Errors. COGT Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Leerink Partnrs Issues Pessimistic Outlook for COGT EarningsJuly 18 at 2:41 AM | americanbankingnews.comLeerink Partnrs Has Pessimistic View of COGT Q2 EarningsJuly 17 at 6:09 AM | marketbeat.comFY2027 Earnings Forecast for COGT Issued By Leerink PartnrsJuly 17 at 3:49 AM | americanbankingnews.comJefferies Raises Cogent Biosciences (COGT) PT, Keeps Buy RatingJuly 16 at 4:59 PM | msn.comWhat is Leerink Partnrs' Estimate for COGT FY2027 Earnings?July 16 at 7:33 AM | marketbeat.comFairmount Funds Management Llc Acquires 2,777,777 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) StockJuly 16 at 4:09 AM | americanbankingnews.comInsider Buying: Cogent Biosciences, Inc. (NASDAQ:COGT) Director Acquires 2,777,777 Shares of StockJuly 15 at 4:13 AM | insidertrades.comCogent Biosciences, Inc. (NASDAQ:COGT) Director Fairmount Funds Management Llc Acquires 2,777,777 SharesJuly 14, 2025 | marketbeat.comCogent Biosciences Announces Closing of Upsized Public Offering of ...July 12, 2025 | morningstar.comMJPMorgan Chase & Co. Boosts Cogent Biosciences (NASDAQ:COGT) Price Target to $29.00July 12, 2025 | americanbankingnews.comHC Wainwright Cuts Earnings Estimates for Cogent BiosciencesJuly 12, 2025 | americanbankingnews.comHC Wainwright Issues Positive Forecast for Cogent Biosciences (NASDAQ:COGT) Stock PriceJuly 11, 2025 | americanbankingnews.comCogent Biosciences (NASDAQ:COGT) Price Target Raised to $9.00July 11, 2025 | americanbankingnews.comLeerink Partnrs Issues Negative Forecast for COGT EarningsJuly 11, 2025 | americanbankingnews.comCogent Biosciences (NASDAQ:COGT) Trading 9% Higher Following Analyst UpgradeJuly 11, 2025 | americanbankingnews.comCogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesJuly 10, 2025 | globenewswire.comCogent Biosciences (NASDAQ:COGT) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst SaysJuly 10, 2025 | marketbeat.comLeerink Partnrs Has Pessimistic View of COGT Q4 EarningsJuly 10, 2025 | marketbeat.comHC Wainwright Issues Pessimistic Estimate for COGT EarningsJuly 10, 2025 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Sees Unusually-High Trading Volume on Analyst UpgradeJuly 10, 2025 | americanbankingnews.comCogent Biosciences Announces Proposed $150 Million Public Offering of Common Stock - MorningstarJuly 9, 2025 | morningstar.comMJanuary 2026 Options Now Available For Cogent BiosciencesJuly 9, 2025 | nasdaq.comCogent: Positive Data In NonAdvSM Bodes Well For 2nd Half AdvSM Treatment ResultsJuly 9, 2025 | seekingalpha.comCogent Biosciences (NASDAQ:COGT) Trading 9% Higher on Analyst UpgradeJuly 9, 2025 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Stock Price Expected to Rise, Jefferies Financial Group Analyst SaysJuly 9, 2025 | americanbankingnews.comCogent Biosciences Target of Unusually High Options Trading (NASDAQ:COGT)July 9, 2025 | americanbankingnews.comCogent Biosciences prices upsized capital raise of $200M via issuance of stock offeringJuly 9, 2025 | msn.comCogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common StockJuly 8, 2025 | globenewswire.comCogent Biosciences Shares Fall After Public Offering NewsJuly 8, 2025 | marketwatch.comCogent Biosciences Announces Proposed $150 Million Public Offering of Common StockJuly 8, 2025 | globenewswire.comCogent Biosciences (NASDAQ:COGT) Sees Unusually-High Trading Volume After Analyst UpgradeJuly 8, 2025 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Price Target Raised to $22.00July 8, 2025 | marketbeat.comCogent Biosciences' (COGT) "Buy" Rating Reiterated at GuggenheimJuly 8, 2025 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Stock Price Expected to Rise, Robert W. Baird Analyst SaysJuly 8, 2025 | marketbeat.comCogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by BrokeragesJuly 8, 2025 | marketbeat.comLeerink Partners Issues Positive Forecast for Cogent Biosciences (NASDAQ:COGT) Stock PriceJuly 8, 2025 | americanbankingnews.comInvestors Purchase High Volume of Put Options on Cogent Biosciences (NASDAQ:COGT)July 8, 2025 | americanbankingnews.comJefferies Financial Group Forecasts Strong Price Appreciation for Cogent Biosciences (NASDAQ:COGT) StockJuly 7, 2025 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Stock Price Expected to Rise, Leerink Partners Analyst SaysJuly 7, 2025 | marketbeat.comStock Traders Purchase High Volume of Cogent Biosciences Put Options (NASDAQ:COGT)July 7, 2025 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Shares Gap Up - What's Next?July 7, 2025 | marketbeat.comCogent Biosciences stock surges after positive trial resultsJuly 7, 2025 | investing.comCogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced Systemic MastocytosisJuly 7, 2025 | globenewswire.comWedbush Increases Earnings Estimates for Cogent BiosciencesJuly 3, 2025 | marketbeat.comWhat is Lifesci Capital's Estimate for COGT Q2 Earnings?July 1, 2025 | marketbeat.comCogent Biosciences' (COGT) "Neutral" Rating Reaffirmed at WedbushJune 30, 2025 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Given "Hold" Rating at Needham & Company LLCJune 17, 2025 | marketbeat.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Cabaletta Bio (CABA), Cogent Biosciences (COGT) and Biogen (BIIB)June 14, 2025 | theglobeandmail.comBank of America Corp DE Reduces Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT)June 14, 2025 | marketbeat.comCogent Biosciences, Inc. (NASDAQ:COGT) Receives Average Recommendation of "Moderate Buy" from AnalystsJune 13, 2025 | marketbeat.com Get Cogent Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for COGT and its competitors with MarketBeat's FREE daily newsletter. Email Address COGT Media Mentions By Week COGT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. COGT News Sentiment▼0.110.96▲Average Medical News Sentiment COGT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. COGT Articles This Week▼204▲COGT Articles Average Week Get Cogent Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for COGT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CRISPR Therapeutics News Vaxcyte News Cytokinetics News Metsera News ADMA Biologics News Krystal Biotech News Akero Therapeutics News Avidity Biosciences News PTC Therapeutics News Arcellx News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:COGT) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cogent Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
